Advanced search
Publication Cover
Expert Review of Hematology Volume 6, 2013 - Issue 1
Submit an article Journal homepage
1,259
Views
5
CrossRef citations to date
0
Altmetric
Editorial

Heads or tails? Choosing a salvage therapy for relapsed/refractory Hodgkin lymphoma

Alan P Skarbnik Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA.
&
Barbara Pro Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA. [email protected]
Pages 1-3 | Published online: 10 Jan 2014

References

  • Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 62(1), 10–29 (2012).
  • Hoppe R. Hodgkin Lymphoma (2nd Edition). Lippincott Williams & Wilkins, PA, USA (2007).
  • Connors JM. State-of-the-art therapeutics: Hodgkin’s lymphoma. J. Clin. Oncol. 23(26), 6400–6408 (2005).
  • Viviani S, Zinzani PL, Rambaldi A et al.; Michelangelo Foundation; Gruppo Italiano di Terapie Innovative nei Linfomi; Intergruppo Italiano Linfomi. ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned. N. Engl. J. Med. 365(3), 203–212 (2011).
  • Majhail NS, Weisdorf DJ, Defor TE et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin’s lymphoma. Biol. Blood Marrow Transplant. 12(10), 1065–1072 (2006).
  • The International ChlVPP Treatment Group. ChlVPP therapy for Hodgkin’s disease: experience of 960 patients. Ann. Oncol. 6(2), 167–172 (1995).
  • Aparicio J, Segura A, Garcerá S et al. ESHAP is an active regimen for relapsing Hodgkin’s disease. Ann. Oncol. 10(5), 593–595 (1999).
  • Colwill R, Crump M, Couture F et al. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin’s disease before intensive therapy and autologous bone marrow transplantation. J. Clin. Oncol. 13(2), 396–402 (1995).
  • Josting A, Rudolph C, Reiser M et al.; Participating Centers. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin’s disease. Ann. Oncol. 13(10), 1628–1635 (2002).
  • Montoto S, Camós M, López-Guillermo A et al. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease. Cancer 88(9), 2142–2148 (2000).
  • Fermé C, Bastion Y, Lepage E et al. The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin’s disease. Ann. Oncol. 6(6), 543–549 (1995).
  • Moskowitz CH, Kewalramani T, Nimer SD, Gonzalez M, Zelenetz AD, Yahalom J. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin’s disease. Br. J. Haematol. 124(5), 645–652 (2004).
  • Sirohi B, Cunningham D, Powles R et al. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma. Ann. Oncol. 19(7), 1312–1319 (2008).
  • Schmitz N, Pfistner B, Sextro M et al.; German Hodgkin’s Lymphoma Study Group; Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet 359(9323), 2065–2071 (2002).
  • Moskowitz CH, Nimer SD, Zelenetz AD et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 97(3), 616–623 (2001).
  • Rodriguez J, Rodriguez MA, Fayad L et al. ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin’s disease. Blood 93(11), 3632–3636 (1999).
  • Santoro A, Magagnoli M, Spina M et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin’s lymphoma. Haematologica 92(1), 35–41 (2007).
  • Bartlett NL, Niedzwiecki D, Johnson JL et al.; Cancer Leukemia Group B. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin’s lymphoma: CALGB 59804. Ann. Oncol. 18(6), 1071–1079 (2007).
  • Younes A, Gopal AK, Smith SE et al. Results of a pivotal Phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J. Clin. Oncol. 30(18), 2183–2189 (2012).
  • Fanale M, Fayad L, Pro B et al. Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma. Br. J. Haematol. 154(2), 284–286 (2011).
  • Younes A, Sureda A, Ben-Yehuda D et al. Panobinostat in patients with relapsed/refractory Hodgkin’s lymphoma after autologous stem-cell transplantation: results of a Phase II study. J. Clin. Oncol. 30(18), 2197–2203 (2012).
  • Johnston PB, Pinter-Brown L, Rogerio J. Open-label, single-arm, Phase II study of everolimus in patients with relapsed/refractory classical hodgkin lymphoma. ASH Annual Meeting Abstracts, Abstract 2717, 118 (2011).
  • Fehniger TA, Larson S, Trinkaus K et al. A Phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 118(19), 5119–5125 (2011).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.